Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2026 Jan;58(1):221-231.
doi: 10.4143/crt.2024.1104. Epub 2025 Mar 5.

Detection Ability of Quality of Life Changes and Responsiveness of the KOQUSS-40 and the EORTC QLQ-C30/STO22 in Patients Who Underwent Gastrectomy: A Prospective Comparative Study

Affiliations
Observational Study

Detection Ability of Quality of Life Changes and Responsiveness of the KOQUSS-40 and the EORTC QLQ-C30/STO22 in Patients Who Underwent Gastrectomy: A Prospective Comparative Study

Bang Wool Eom et al. Cancer Res Treat. 2026 Jan.

Abstract

Purpose: The aim of this study is to compare the detection ability of quality of life (QoL) changes and responsiveness of the KOrean QUality of life in Stomach cancer patients Study group (KOQUSS)-40 and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ).

Materials and methods: A multicenter prospective observational study was conducted to evaluate QoL changes after various gastrectomies between January 2021 and April 2022. Participants were instructed to complete the KOQUSS-40 and EORTC QLQ-C30/STO22 preoperatively and at 1, 3, 6, and 12 months postoperatively. QoL changes over time and QoL responsiveness were assessed for each questionnaire.

Results: Data from 491 patients who underwent curative gastrectomy for gastric cancer at 22 institutions were analyzed. The summary scores of the KOQUSS-40 and EORTC QLQ-STO22 showed significant differences between the total and proximal gastrectomy groups (p=0.044 and p=0.038, respectively), but no difference was observed for the EORTC QLQ-C30. Dysphagia on the KOQUSS-40 was significantly different between the total and proximal gastrectomy groups (p=0.031); however, dysphagia on the EORTC QLQ-STO22 did not differ. The responsiveness of the KOQUSS-40 was similar to that of the EORTC QLQ in patients who experienced ≥ 10% body weight loss, but approximately 10% less in patients receiving adjuvant chemotherapy than the EORTC QLQ.

Conclusion: KOQUSS-40 has several advantages over EORTC QLQ-C30/STO22 when comparing QoL between the total and proximal gastrectomy groups. The findings provide information for researchers investigating the QoL of patients who have undergone curative gastrectomy for gastric cancer.

Keywords: Gastrectomy; Quality of life; Stomach neoplasms; Surveys and Questionnaires.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

Conflict of interest relevant to this article was not reported.

Figures

Fig. 1.
Fig. 1.
Consort diagram.
Fig. 2.
Fig. 2.
Postoperative changes of summary scores of the KOQUSS-40 (A), EORTC QLQ-C30 (B), and EORTC QLQ-STO22 (C). DG, distal gastrectomy; EORTC QLQ, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; KOQUSS, KOrean QUality of life in Stomach cancer patients Study group; n.s., not significant; PG, proximal gastrectomy; PPG, pylorus-preserving gastrectomy; TG, total gastrectomy. *p < 0.05.
Fig. 3.
Fig. 3.
Postoperative changes of common symptoms. (A) Indigestion of the KOQUSS-40. (B) Eating restriction of the EORTC QLQ-STO22. (C) Dysphagia of the KOQUSS-40. (D) Dysphagia of the EORTC QLQ-STO22. (E) Reflux of the KOQUSS-40. (F) Reflux of the EORTC QLQ-STO22. DG, distal gastrectomy; EORTC QLQ, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; KOQUSS, KOrean QUality of life in Stomach cancer patients Study group; n.s., not significant; PG, proximal gastrectomy; PPG, pylorus-preserving gastrectomy; TG, total gastrectomy. *p < 0.05.

References

    1. Choi KS, Jun JK, Suh M, Park B, Noh DK, Song SH, et al. Effect of endoscopy screening on stage at gastric cancer diagnosis: results of the National Cancer Screening Programme in Korea. Br J Cancer. 2015;112:608–12. - PMC - PubMed
    1. Khanderia E, Markar SR, Acharya A, Kim Y, Kim YW, Hanna GB. The influence of gastric cancer screening on the stage at diagnosis and survival: a meta-analysis of comparative studies in the Far East. J Clin Gastroenterol. 2016;50:190–7. - PubMed
    1. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–21. - PubMed
    1. Kim IH. Emerging targets for systemic treatment of gastric cancer: HER2 and beyond. J Gastric Cancer. 2024;24:29–56. - PMC - PubMed
    1. Eom BW, Yoon HM, Kim YW, Min JS, An JY, Hur H, et al. Quality of life and nutritional outcomes of stomach-preserving surgery for early gastric cancer: a secondary analysis of the SENORITA randomized clinical trial. JAMA Surg. 2024;159:900–8. - PMC - PubMed

LinkOut - more resources